Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS prot

Malaria remains a major cause of morbidity and mortality worldwide with 219 million infections and 435,000 deaths predominantly in Africa. The infective Plasmodium sporozoite is the target of a potent humoral immune response that can protect murine, simian and human hosts against challenge by malaria-infected mosquitoes. Early murine studies demonstrated that sporozoites or subunit vaccines based on the sporozoite major surface antigen, the circumsporozoite (CS) protein, elicit antibodies that primarily target the central repeat region of the CS protein. In the current murine studies, using monoclonal antibodies and polyclonal sera obtained following immunization with P. falciparum sporozoites or synthetic repeat peptides, we demonstrate differences in the ability of these antibodies to recognize the major and minor repeats contained in the central repeat region. The biological relevance of these differences in fine specificity was explored using a transgenic P. berghei rodent parasite expressing the P. falciparum CS repeat region. In these in vitro and in vivo studies, we demonstrate that the minor repeat region, comprised of three copies of alternating NANP and NVDP tetramer repeats, contains an epitope recognized by sporozoite-neutralizing antibodies. In contrast, murine monoclonal antibodies specific for the major CS repeats (NANP)n could be isolated from peptide-immunized mice that had limited or no sporozoite-neutralizing activity. These studies highlight the importance of assessing the fine specificity and functions of antirepeat antibodies elicited by P. falciparum CS-based vaccines and suggest that the design of immunogens to increase antibody responses to minor CS repeats may enhance vaccine efficacy.

The repeat region of the circumsporozoite (CS) protein of all Plasmodium species contains a species-specific immunodominant B cell epitope that is recognized by sera of sporozoite-immunized rodents, monkeys and human volunteers, as well as by naturally infected individuals1,2. When sporozoites are targeted by antirepeat antibodies, parasite motility is inhibited thus blocking egress from the site of the mosquito bite into the blood and invasion of host cell hepatocytes thereby preventing subsequent development of blood-stage infection and clinical disease3,4,5,6.

Early studies demonstrated that monoclonal antibody (MAB) specific for CS repeats derived from sporozoite-immunized experimental hosts were protective following passive transfer to susceptible rodents or monkeys. As little as 10 µg of MAB specific for the CS repeats of rodent P. berghei sporozoites was shown to protect naïve rodents against sporozoite challenge and 2 mg of MAB specific for the P. vivax CS repeats protected Saimiri monkeys from homologous sporozoite challenge7. In recent studies, passive transfer of 100–300 µg of human MAB specific for P. falciparum CS repeats, derived from volunteers immunized with the CS-based RTS,S vaccine, protected mice against challenge with transgenic P. berghei parasites expressing full length P. falciparum CS protein8.

The demonstration of antibody-mediated protection in experimental hosts has encouraged efforts to design CS-based vaccines that elicit high titer antirepeat antibodies to neutralize sporozoite infectivity. However, despite decades of vaccine research, a protective antirepeat antibody titer remains to be defined and there is limited information on the range of functional antirepeat antibodies elicited following immunization with sporozoites or CS subunit vaccines. The immunodominant repeat region of P. falciparum CS protein is comprised of major and minor tetramer repeat sequences that are conserved in all isolates. In the P. falciparum NF54 strain9, used in the majority of human malaria challenge studies, the CS repeat region is comprised primarily of 37 NANP tetramers (Fig. 1). In addition, there is a minor repeat region comprised of three alternating NVDP and NANP tetramers in the 5’ repeat region, which is adjacent to a CS protein proteolytic cleavage site that plays a role in sporozoite invasion of host cells10,11.

Early studies demonstrated that a major repeat peptide, comprised of three copies of the NANP repeat, (NANP)3, could block binding of monoclonal and polyclonal antirepeat antibodies to P. falciparum sporozoites and P. falciparum CS protein12. The NANP repeats were used in the first CS-based subunit vaccine clinical trials, which tested safety and efficacy of a synthetic peptide-protein conjugate, (NANP)3-TT13, or a recombinant protein R32 containing 32 NANP repeats14. The Phase II trials demonstrated modest protective efficacy following challenge of a small number of immunized volunteers by bites of P. falciparum-infected mosquitoes.

Differences in fine specificity of polyclonal antirepeat antibodies elicited in NANP peptide-immunized simian and rodent hosts were noted in early studies based on peptide ELISA and IFA reactivity with P. falciparum sporozoites15,16. The functional relevance of the variations in fine specificity of antirepeat antibodies could not be defined in these early studies as P. falciparum sporozoites are infective only in human hosts or splenectomized chimpanzees. More recently, the development of transgenic rodent parasites expressing all or parts of the P. falciparum CS protein has provided rodent models to address the role of antibody fine specificity in neutralizing sporozoite infectivity.

In the current paper, we used transgenic P. berghei sporozoites expressing P. falciparum CS repeats17 to examine neutralizing activity of MAB and polyclonal antirepeat antibodies derived from sporozoite- or peptide-immunized mice. We found that MAB specific for the minor repeats were protective in vitro and in vivo. In addition, several MABs elicited by immunization with major repeats could be isolated, which did not have neutralizing activity. These studies on fine specificity of sporozoite-neutralizing antibodies have important implications for vaccine design and analysis of functional humoral responses to the P. falciparum CS repeat region.

Fine specificity of MAB derived from mice immunized with P. falciparum sporozoites

CS-specific MABs derived from P. falciparum sporozoite-immunized mice18 were analysed for fine specificity by ELISA using either the major repeats (NANP)3 or minor repeats (DPNANPNV)2 as coating antigen. MAB fine specificity varied, either cross-reacting with both the minor and major repeats, as exemplified by MAB 2A10, or skewing toward the minor repeat region with little or no reactivity with the major repeats as shown by MAB 2F9, 2C2 and 4H3 (Fig. 2a). All of the MABs specific for minor repeats also reacted with P. falciparumsporozoites by indirect immunofluorescence assay (IFA) (data not shown).

MABs recognizing only the minor repeats were compared to cross-reacting MAB 2A10 using a Transgenic Sporozoite Neutralizing Assay (TSNA) to measure ability of the MAB to inhibit invasion of PfPb sporozoites into hepatoma cells (Fig. 2b). The minor repeat-specific MABs 2C2 and 4H3 demonstrated dose-dependent sporozoite-neutralizing activity. These MAB gave >90% reduction in parasite rRNA copy number when tested at 25 and 12.5 µg/ml, similar to inhibition obtained with MAB 2A10 that cross-reacted with both major and minor repeats. The minor repeat-specific MABs were also inhibitory at 3.125 µg/ml, the lowest concentration tested. MAB 3D11, specific for P. berghei CS repeats, did not block PfPb sporozoite invasion of hepatoma cells. These results provide evidence that antibodies specific for the P. falciparum CS minor repeats can neutralize sporozoite infectivity.

To confirm the specificity of neutralizing activity, a peptide competition TSNA was carried out by preincubating minor repeat-specific MAB 2C2, or cross-reacting MAB 2A10, with either major or minor repeat peptides prior to addition to PfPb sporozoites (Fig. 2c). MAB 2C2 was inhibited by minor repeat peptide (closed squares), but not the major repeat peptide (open squares), confirming that antibody neutralizing activity was directed at the minor repeats. Interestingly, MAB 2A10, which recognizes both major and minor repeats in peptide ELISA, was primarily inhibited by the minor repeat peptide. Preincubation of MAB 2A10 with the major repeat peptide gave minimal inhibition of sporozoite neutralization. The peptide competition TSNA confirms that the CS minor repeats are targets of neutralizing antibodies.

Major or minor repeat peptides elicit antibodies that differ in fine specificity

To further investigate fine specificity of neutralizing antibodies, mice were immunized with tetrabranched peptides containing either the minor repeats (T1T*)4 or the major repeats (BT*)4. Previous studies had found that a related immunogen (T1BT*)4 elicited antirepeat antibodies in mice and human volunteers19,20.

Mice were immunized subcutaneously (s.c.) with three doses of (T1T*)4 or (BT*)4 in QS21 adjuvant. Immune sera of C57BL/6 mice immunized with (T1T*)4 reacted equally with minor repeat peptide (DPNANPNV)2 and with major repeat peptide (NANP)3 in ELISA (Fig. 3a). In contrast, immune sera of mice immunized with major repeat peptide (BT*)4 recognized the major repeats with four-fold higher titer than the minor repeat peptide. Skewing of the fine specificity of the antirepeat antibody response was also observed in BALB/c mice immunized with (T1T*)4 or (BT*)4 (Supplementary Table 1). The BALB/c mice immunized with (T1T*)4developed eight-fold higher titer against T1 minor repeats compared to major repeats while immunization with (BT*)4 elicited eight-fold higher titer against B major repeats.

To examine the function of the antirepeat antibodies elicited by minor repeat peptide, the serum from (T1T*)4 immunized C57BL/6 mice was tested for ability to neutralize PfPb sporozoite infectivity in vitro. Sera of BALB/c mice were not analyzed in TSNA due to nonspecific resistance to P. berghei that comprise the genetic backbone of the PfPb transgenic sporozoites21,22.

In the TSNA, the sera of C57BL/6 mice immunized with (T1T*)4 had high levels of neutralizing activity, with a 1:10 serum dilution inhibiting >90% sporozoite invasion of hepatoma cells (Fig. 3b). Inhibition by the (T1T*)4 immune serum was comparable to that observed with 25 µg/ml MAB 2A10. The neutralizing activity in (T1T*)4 serum was specific for CS repeats as no inhibition was obtained with serum obtained prior to immunization (hatched bars), which gave 18 S rRNA copy number similar to control wells without serum (PBS, horizontal hatched bar). In contrast, serum of C57BL/6 immunized with the major repeat peptide, (BT*)4, did not inhibit sporozoite infectivity at the lowest dilution tested (1:5). Since previous studies have demonstrated that high levels of antibodies elicited by (NANP)n constucts can inhibit P. falciparum sporozoites12,13,14,23, the lack of neutralizing activity of (BT*)4 serum suggests that magnitude, as well as specificity of the antirepeat antibodies, is important in neutralizing sporozoite infectivity.

Linear peptide containing minor repeats also elicits sporozoite-neutralizing antibodies

To determine if differences in the fine specificity of the antirepeat antibodies were dependent on peptide configuration, mice were immunized with linear T1T* peptides using various adjuvant formulations. Previous murine studies had found that immunogenicity of related T1BT* sequence was comparable using either branched or linear peptides as immunogens24. Following three s.c. injections of linear T1T* peptide in various adjuvants in C57BL/6 and BALB/c mice, the linear T1T* peptide was found to elicit antirepeat ELISA titers comparable in magnitude to those elicited by the more complex tetrabranched (T1T*)4 (Fig. 3a, Supplementary Fig. 1). Linear peptides formulated in oil-in-water adjuvants, Montanide ISA 720 or ISA 51, or by the inclusion of the TLR 9 agonist, CpG, elicited ELISA titers that were an order of magnitude higher than peptide without adjuvant (PBS). With all adjuvant formulations, immune sera IFA titers with P. falciparum sporozoites were similar in magnitude to the repeat ELISA titer.

In a second experiment, a head-to-head comparison of tetrabranched (T1T*)4 peptide versus linear T1T* peptide formulated in ISA 720 adjuvant was shown to elicit comparable antirepeat antibodies responses with ELISA GMT 1.6 × 104 and 5.6 × 104, respectively. TSNA demonstrated that immune sera from C57BL/6 mice immunized with either linear T1T* peptide or with (T1T*)4 peptide significantly decreased parasite rRNA copy numbers when compared to Day 0 sera (adjusted P = 0.0024 and P = 0.042, respectively) (Supplementary Fig. 2).

The antirepeat antibodies elicited by immunization with the linear T1T* peptide were also functional in vivo (Fig. 4b). Challenge of T1T* /ISA 720 immunized C57BL/6 mice by exposure to bites of mosquitoes infected with PfPb transgenic parasites demonstrated >90% reduction of liver parasite burden when compared to adjuvant only control (adjusted *P < 0.012). Protection in the challenged mice was antibody mediated, as depletion of CD4 + or CD8 + T cells prior to challenge did not abrogate immune resistance. Similar to intact T1T* immunized mice, T-cell-depleted T1T* immunized mice had >90% reduction of parasite 18 S rRNA copy number when compared to mice immunized with ISA 720 adjuvant only. There was no significant difference in rRNA copy numbers in CD4- and CD8-depleted mice compared to intact mice (adjusted P = 0.8317 and P = 0.7685, respectively). The lack of a direct role for cell mediated immunity in resistance to challenge is consistent with our previous studies in repeat peptide-immunized mice24.

To confirm that in vivo sporozoite-neutralizing activity was antibody mediated, serum of mice immunized with T1T* /ISA 720 was passively transferred by intravenous injection (i.v.) into naïve recipients prior to challenge by exposure to the bites of PfPb-infected mosquitoes (Fig. 4c). The recipients of T1T*/ISA 720 immune serum had >90% reduction of parasite density in liver compared to naïve mice (*P = 0.0010), confirming that protection in the T1T* immunized mice was antibody mediated.

MAB specific for major or minor repeats derived from peptide-immunized mice

To further define the fine specificity of the antirepeat antibody response, MAB were derived from the mice immunized with either the T1T* minor repeat or BT* major repeat peptides. When screened by ELISA, MAB specific for either minor or major repeats could be readily obtained from the mice immunized with each immunogen (Fig. 5). MABs 3E9 and 3C4, two representative MAB from T1T* immunized mice, reacted with minor repeat (closed symbols) but not major repeats (open symbols) (Fig. 5a). Conversely, two representative MABs from BT* immunized mice, MABs 3F11 and 3E7, gave high levels of reactivity with major, but not minor repeats (Fig. 5b). MAB 2A10, cross-reacted with both minor and major repeats and confirms comparable peptide coating in each of the peptide ELISA.

When tested in TSNA, the minor repeat-specific MAB 3C4 inhibited PfPb sporozoite invasion into hepatoma cells at levels comparable to or greater than MAB 2A10 derived from P. falciparum sporozoite-immunized mice (Fig. 6a). In contrast, several MAB derived from mice immunized with the major repeat peptide were not inhibitory at the highest concentration tested (12.5 µg/ml) (Fig. 6b). Therefore, as illustrated by these major repeat-specific MABs, high levels of antirepeat antibodies as measured by ELISA do not necessarily predict neutralizing activity against viable parasites.

A recent malaria vaccine milestone was reached with the WHO supported pilot implementation of a CS-based vaccine, RTS,S, in three African nations25. RTS,S vaccine efficacy was 30–50% in infants and children, respectively26, and efforts to improve CS-based vaccines are ongoing in many laboratories. While evidence for protection mediated by antirepeat antibodies has been obtained in RTS,S clinical trials23,26, a correlate of protective immunity for CS-based vaccines has not yet been defined. A better understanding of the antibody response to P. falciparum CS repeats is required to design more efficacious vaccines.

In testing of polyclonal and monoclonal antibodies, we found variation in both fine specificity and function of antibodies specific for P. falciparum CS repeats. MAB derived from mice immunized with P. falciparum sporozoites, such as MAB 2A10, reacted with both major and minor repeats, while other MAB skewed to recognition of the minor repeats (Fig. 2a). MAB specific for the minor repeats neutralized PfPb sporozoite infectivity in vitro similar to MAB 2A10 and preincubation with minor, but not major, repeat peptide decreased sporozoite-neutralizing activity (Fig. 2b, c).

Antibodies that recognized the minor CS repeats could also be elicited in C57BL/6 mice by immunization with peptide immunogens containing the T1 minor repeats (Figs. 3a, 4a). A similar skewing of antibodies to minor repeat could be elicited by T1T* peptide immunogens in BALB/c mice (Supplementary Table 1) indicating that ability to elicit antibodies to the minor repeats is not limited by genetic background.

The antibodies elicited by minor repeat peptide immunogens neutralized sporozoite infectivity in vitro in a dose-dependent manner (Fig. 3b). Consistent with in vitro results, protection in C57BL/6 mice immunized with a linear T1T* peptide was antibody mediated (Fig. 4b, c). T-cell-depleted T1T*-immunized mice had similar levels of protection as intact mice and passive transfer of immune serum from these mice protected naïve recipients following PfPb challenge. Minor repeat-specific MAB derived from T1T* immunized mice efficiently neutralized PfPb sporozoite infectivity in vitro (Fig. 6a). Of note, several MAB specific for the major repeats, isolated from mice immunized with BT* major repeat peptide, lacked neutralizing activity when tested in TSNA (Fig. 6b), illustrating that not all antirepeat antibodies are equally effective in neutralizing sporozoite infectivity.

The current findings demonstrate that the P. falciparum CS minor repeat region contains an important sporozoite-neutralizing epitope. The functional variations of the antirepeat antibody response could have potentially significant biological consequences. Vaccine efficacy would be lower if the majority of antibodies elicited by vaccines recognize only the more numerous major repeats and have minimal neutralizing capacity, as in Fig. 6b, in contrast to specifically targeting, or cross-reacting, with the minor repeats, as in Fig. 6a. The presence of protective and nonprotective epitopes within the repeats potentially provides an explanation for the paradox of why the parasite would express a highly immunogenic repeat region. As originally proposed by Anders for repeat epitopes of blood-stage antigens27, the more numerous major repeats may potentially serve as an immunological “smoke screen” to divert responses away from the development of inhibitory antibody responses. The design of immunogens that contain only minor repeats in the absence of major repeats, as in the T1T* peptide immunogens, may drive responses toward a higher proportion of functional minor repeat-specific antibodies and away from major repeat antibodies that are potentially non-neutralizing. Analysis of a larger panel of MAB is required to determine if the frequency of neutralizing vs non-neutralizing antibodies is increased following immunization with minor repeat peptide as compared to major repeat peptides.

A mechanism for why antibodies to minor repeats may be more protective was suggested by recent studies using human MABs derived from sporozoite-immunized malaria-naïve or African adults28,29. These human MAB were dual specific and bound to a unique junctional epitope within the KQPADGNPDPNANP sequence preceding the CS repeat region, as well as to NANP repeats. Passive transfer of human MAB reactive with the junctional epitope derived from P. falciparum sporozoite-immunized Tanzanian adults protected humanized mice against P. falciparum sporozoite challenge28. The junctional epitope is located three amino acids upstream of a previously identified proteolytic CS cleavage site in Region 110. A human MAB specific for the junctional epitope blocked cleavage of P. falciparum CS protein29. MAB 2A10, which cross-reacts with both major and minor repeats, can also inhibit the proteolytic processing of CS protein30.

The human MABs specific for the junctional epitope recognized two distinct minimal epitopes within the junctional region, DPNANP28 and NPN29. BALB/c mice immunized with a (NPDP)19peptide containing the junctional epitope, elicited high titers of antibodies specific for the junctional epitope that were poorly reactive with repeats and did not have sporozoite-neutralizing activity28. Additional studies by Oyen et al. have shown that dual binding of antibody to both the junctional and repeat epitopes was required for neutralizing activity31.

The minor repeat peptide DPNANPNVDPNANPNV, used as immunogen in the current studies (Fig. 1), contains two copies of the junctional epitopes identified by Kisalu et al.29 (indicated in bold) and Tan et al. (underlined)28. Whether the antibodies specific for the minor repeats, or MAB that cross-react with minor repeats such as MAB 2A10, can also recognize the junctional epitope and thus show dual specificity of binding to CS remains to be determined. Studies to examine affinity of larger panels of murine anti-T1 MAB and to identify key residues in the T1 epitope by positional scanning and generation of peptide-antibody complexes are planned.

Recent immunoglobulin gene sequencing studies have also detected a range of fine specificity of human recombinant MAB specific for CS repeats derived from volunteers immunized by exposure to P. falciparum sporozoites under chloroquine prophylaxis32. The human MAB recognized multiple epitopes within the P. falciparum CS repeat region, including NVDP and NANPNVDP. The current studies in sporozoite- and peptide-immunized mice are consistent with the diversity of antirepeat antibodies found in the MAB from sporozoite-immunized human volunteers and support the use of the more experimentally amendable small rodent model for analysis of antibody responses to P. falciparum CS repeat region relevant to the design of more efficacious human malaria vaccines.

The variable fine specificity and function of the antirepeat antibodies detected in the current studies has significant implications for the design of subunit vaccines that elicit inhibitory, rather than nonfunctional, antirepeat antibodies. Epitope-focused vaccines based on the CS minor repeat, such as the T1T* immunogen, potentially can focus the immune responses on sporozoite-neutralizing epitopes and reduce immune response to more numerous but potentially less protective major repeats. Our current studies, showing that immunization with minor repeat peptides elicits neutralizing antibodies that inhibit sporozoite infectivity in vitro and in vivo, combined with recent findings with human MABs28,29,32, provide a framework for the design of subunit vaccines that elicit optimal levels of neutralizing antibodies to more effectively target CS protein on P. falciparum sporozoites.

Ethics statement

Studies in mice were approved by the Institutional Animal Care and Use Committee, NYU School of Medicine (Protocol 1501081) and conducted following recommendations specified in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

Peptides

For the peptide constructs, the P. falciparum CS major repeats were represented by the (NANP)3 sequence (designated “B” epitope) (Fig. 1). The 5’ minor repeat region, comprised of alternating NVDP and NANP repeats, was represented by the peptide sequence (DPNANPNVDPNANPNV). The minor repeat sequence was designated T1, as it also contains the first CS-specific CD4 + T helper cell epitope identified in sporozoite-immunized human volunteers33. The major or minor repeat sequences were synthesized in tandem with a malaria universal Th cell epitope, EYLNKIQNSLSTEWSPCSVT, designated T* (Fig. 1). The T* T helper cell epitope, located in the C-terminus of the P. falciparum CS protein (NF54 isolate), is recognized in the context of multiple murine and human class II molecules and was included in all constructs to overcome genetic restrictions34,35,36. The peptide immunogens were synthesized either as a tetrabranched construct containing the respective repeat and the T* sequences in each of four branches, or as a linear peptide using standard F-Boc peptide chemistry (AnaSpec, San Jose, CA).

Antibodies

Fine specificity and function of antirepeat antibodies was carried out using polyclonal sera elicited by peptide immunization of C57BL/6 (H-2b) and BALB/c mice (H-2d) mice (Jackson Labs, Bar Harbor Maine). BALB/c mice were included in the initial immunogenicity studies to examine genetic restriction of humoral immunity elicited by the peptide immunogens. Since BALB/c are nonresponders to CS repeats, the peptides were synthesized to contain T*, a universal T helper cell epitope36,37,38,39 (Fig. 1). BALB/c are high responders to the T* T helper cell epitope, while C57BL/6 are high responders to CS repeats and the T* epitope36,39.

Mice were immunized subcutaneously (s.c.) at 14 day intervals with three doses of 50 µg peptide with or without various adjuvants. Adjuvants included QS21, a purified saponin derivative (Antigenics Inc., Woburn, MA); water-in-oil adjuvants, either Montanide ISA 51, a mineral oil emulsion comparable to Freund’s Incomplete Adjuvant, or ISA 720 a natural metabolizable nonmineral oil and mannide monooleate emulsifier (Seppic, Inc, Fairfield, NJ); or CpG 1826, a TLR 9 agonist comprised of synthetic oligodeoxynucleotide containing unmethylated CpG motifs (InvivoGen, San Diego, CA).

MAB 2A10, a monoclonal antibody specific for CS repeats (ATCC BEI MRA-183), generated in our laboratory from mice immunized with P. falciparum sporozoites18, was included as a standard. MAB 2A10 has been studied extensively in the analysis and development of CS subunit vaccines40,41,42,43. MAB 3D11, specific for P. berghei CS repeats44, was included as a negative control, as the PfPb transgenics express P. falciparum CS repeat region within the P. berghei CS protein17. MAB 2A10 neutralizes infectivity of PfPb sporozoites but not P. bergheisporozoites and, conversely, MAB 3D11 neutralizes P. berghei, but not PfPb sporozoites17.

Serological assays

MAB fine specificity and antirepeat IgG endpoint titers in immune sera were determined by ELISA using wells coated with synthetic tetrabranched peptides representing either the major repeat (NANP)3 peptide or minor repeat (DPNANPNV)2 peptide. Two-fold dilutions of MAB or serum were tested and bound antibody was detected by reaction with HRP-labeled anti-mouse IgG (MP Biochemicals, Solon, OH) and TMB/H2O2 substrate (KPL, SeraCare; Gaithersburg, MD). Endpoints were determined as final dilution of serum giving OD > 3X BSA-coated wells. A >4-fold difference in antibody geometric mean titers was considered meaningful. Reactivity with P. falciparum sporozoites was determined by Indirect Immunofluorescence Assay (IFA), as in previous studies39,45.

In vitro studies of antibody function used a Transgenic Sporozoite Neutralization Assay (TSNA), as previously described46,47,48. In the PfPb transgenic rodent parasites, the P. berghei CS repeat region has been replaced with the entire P. falciparum CS repeat region, (NANPNVDP)3(NANP)15NVDP(NANP)19, as well as 26 aa of the N-terminus, NNEDNEKLRKPKHKKLKQPGDGNPDP preceding the repeat region17. For TSNA, MAB or polyclonal serum at various dilutions were incubated with 2 × 104 PfPb sporozoites for 40 min on ice prior to addition to confluent human hepatoma HepG2 cells (ATCC HB 8065) in cRPMI (RPMI 1640 supplemented with 10%FBS, 50U Penicillin/50 µg Streptomycin, sodium pyruvate, non-essential amino acids, all from Gibco, ThermoFisher, Waltham, MA). Plates were incubated at 5% CO2 for 48 h, with media change at 24 h, followed by extraction of total RNA (PureLink, RNA Mini Kit, ThermoFisher, Waltham, MA). The amounts of parasite 18 S rRNA in each culture extract was quantitated by real-time PCR (qRT-PCR) using cDNA primers specific for 18 S ribosomal RNA (rRNA)46,49. The parasite 18 S rRNA copy number was calculated based on a standard curve generated with known amounts of plasmid 18 S cDNA. To assess the peptide specificity of antibodies mediating sporozoite neutralization, a peptide competition TSNA was carried out in which MAB (25 µg/ml) were pre-incubated with various concentrations of either minor repeat peptide (DPNANPNV)2 or major repeat peptide (NANP)3 for one hour prior to addition of PfPb sporozoites and performance of TSNA per protocol.

For in vivo studies, peptide-immunized and naive C57BL/6 mice were challenged by exposure to the bites of 10–15 PfPb-infected mosquitoes. BALB/c mice were not used in these studies due to nonspecific resistance to P. berghei sporozoites21,22. Following sporozoite challenge, total RNA was extracted from the livers 40-h post-challenge and levels of parasites in the liver quantitated by qRT- PCR, as for in vitro TSNA. In passive transfer studies, immune serum was passively transferred to naïve recipients by intravenous injection 24 h prior to exposure to the bites of PfPb-infected mosquitoes.

Previous studies have found that >90% reduction in PfPb parasite copy number measured by qRT-PCR is associated with delayed parasitemia or sterile immunity24,47,48. The >90% cutoff is consistent with early studies in which i.v. injection of known numbers of sporozoites of rodent and non-human primate Plasmodium species demonstrated that a log reduction in parasite numbers results in a delay in prepatent period or absence of infection50,51.

Statistical analysis

Statistical analysis was carried out using GraphPad Prism version 8.4.2. Differences between control and experimental groups were determined significant by one-way ANOVA with post-hoc Dunnett’s or Tukey’s test to correct for multiple comparisons or unpaired t-test. Normal distribution and equal standard deviation were corroborated. Differences were considered statistically significant at P < 0.05. Adjusted P values for multiple comparison are reported.